CRYSVITA is an antibody that treats the underlying cause of X-linked hypophosphatemia (XLH) by increasing phosphorus levels in the body. People with XLH have too much of a protein called fibroblast growth factor 23 (FGF23), which causes the body to lose much of the phosphorus it needs for bone health.
How CRYSVITA may workThe benefits and risks of CRYSVITA treatment were studied in a total of 126 children with XLH.
In these clinical studies, CRYSVITA was shown to help by:
Increasing and maintaining phosphorus levels in the blood
Healing rickets and helping improve leg abnormalities
Increasing growth
The benefits and risks of CRYSVITA treatment were studied in a total of 148 adults with XLH.
In these clinical studies, CRYSVITA was shown to help by:
Increasing and maintaining phosphorus levels in the blood
Healing fractures and osteomalacia
Improving XLH-related joint stiffnesss
